On 27 April 2011, the FDA announced that it is working with the EMA and Australia’s Therapeutic Goods Administration (TGA) to finalise a permanent pilot programme for joint good manufacturing practice (GMP) inspections at active pharmaceutical ingredient (API) manufacturing facilities.
EMA, FDA and TGA joint GMP inspection programme
Home/Guidelines
|
Posted 13/05/2011
0
Post your comment
The objective of the collaboration on GMP inspections is to spread the workload, allowing more API sites to be monitored.
The EMA and FDA had already announced a pilot programme for joint GMP inspections in August 2010 and had prepared a draft procedure for such a joint venture in September 2010. Adding Australia’s TGA to the collaboration will certainly help to spread their resources further, enabling even more sites to be inspected.
The idea of collaboration to lighten the load is not new for the EMA and FDA. The agencies launched a three year pilot programme on 1 April 2011 that will allow parallel evaluation of quality elements, known as Quality by Design, of selected applications that are submitted to both agencies at the same time.
Related articles
FDA and EMA to join forces on quality
Source: EMA, FDAnews
Policies & Legislation
ANVISA and DINAVISA sign MoU to strengthen border surveillance and regulatory cooperation
Congress pushes biosimilar bills as interchangeability concerns linger
Reports
Central America moves toward joint evaluation of biosimilar medicines
The US$52 billion question: can the US keep biosimilars competitive?
Most viewed articles
The best selling biotechnology drugs of 2008: the next biosimilars targets
Global biosimilars guideline development – EGA’s perspective
Related content
Brazil's ANVISA updates guidance on pharmacokinetic studies for biosimilars
Canada eliminates phase III trial requirement for biosimilar approvals
FDA updates draft biosimilar guidance, signalling greater flexibility for developers
FDA finalizes Guidance on Promotional Labeling and Advertising for biologicals
Related content
Brazil's ANVISA updates guidance on pharmacokinetic studies for biosimilars
Home/Guidelines Posted 20/08/2026
Canada eliminates phase III trial requirement for biosimilar approvals
Home/Guidelines Posted 22/06/2026
FDA updates draft biosimilar guidance, signalling greater flexibility for developers
Home/Guidelines Posted 12/06/2026
FDA finalizes Guidance on Promotional Labeling and Advertising for biologicals
Home/Guidelines Posted 25/05/2026
Most viewed articles
The best selling biotechnology drugs of 2008: the next biosimilars targets
Post your comment